×
English
हिंदी
ગુજરાતી
Home
My Feed
Remove Ads
Get Premium Content
Go Pro @₹99
Credit Cards
Instant Loans
Apply Now
Credit Score
Refer & Earn ₹500
Refer Now
Finance Tracker
Learning Curve
Fixed Deposits
Business Loan
Markets
Markets
FII & DII Activity
Corporate Action
Research Advice
Earnings
Technical Trends
Stock Deals
Intraday Large Deals
Bonds
Webinar
Pre Market
Stock Scanner
Sector Analysis
Unlisted Shares
Stock Updates
Monsoon Tracker
Seasonality Analysis
Crypto Dashboard
Web Stories
Tax Calculator
Forum
Gold Rate
Silver Rate
IFSC Code Finder
Storyboard18
IPO
Economic Indicators
Economic Calendar
Global Markets
US Markets
ETFs
Indian Indices
News
News
Tech/Startups
Auto
Research
Opinion
Politics
Personal Finance
EPF Guide
Real Estate
Portfolio
Watchlist
Personal Finance
Personal Finance
Loans
Fixed Deposit Comparison
Fixed Deposit Interest Calculator
Moneycontrol - SecureNow Health Insurance ratings
Mutual Funds
Mutual Funds
Performance Tracker
Top ranked funds
My Portfolio
Top performing Categories
Forum
New Fund Offers
MF Simplified
Commodities
Mutual Funds
Gold Rate
Silver Rate
Currencies
Cryptocurrency
Media
Live TV & Shows
Video
Podcast
Photos
Invest Now
Trade like Experts
Specials
Pharma Industry Conclave
Unlocking opportunities in Metal and Mining
Mutual Fund Summit 2025
Advanced Technical Charts
International
Get App
Be a
Pro
Home
PRO
Markets
News
Editor’s Picks
Tech
India
Learning Curve
Portfolio
Watchlist
Commodities
MF
Personal Finance
Forum
Videos
you are here:
Home
News
Ads
Zydus Lifescience Q1 PAT seen up 58.6% YoY to Rs 839.1 cr: Nirmal Bang
Zydus Lifesciences Q1 PAT may dip 10.6% YoY to Rs 505.2 cr: Prabhudas Lilladher
Cadila Healthcare Q3 PAT seen up 3.2% YoY to Rs 544 cr: Prabhudas Lilladher
Cadila Healthcare Q2 PAT seen up 19% YoY to Rs 563.3 cr: Prabhudas Lilladher
Cadila Healthcare Q1 PAT seen up 63.9% YoY to Rs 744 cr: KRChoksey
Cadila HC Q1 PAT seen up 10.7% YoY to Rs 502.5 cr: ICICI Direct
Cadila Q4 PAT seen up 13.7% YoY to Rs. 505 cr: Sharekhan
Cadila Healthcare Q3 PAT seen up 37.6% YoY to Rs. 373.9 cr: Prabhudas Lilladher
Cadila Healthcare Q2 PAT may dip 23% YoY to Rs. 321.5 cr: Emkay
Cadila Healthcare Q1 PAT may dip 22.4% YoY to Rs. 366.7 cr: Prabhudas Lilladher
Cadila Healthcare Q4 PAT may dip 28.9% YoY to Rs. 419.9 cr: Prabhudas Lilladher
Cadila Q3 PAT may dip 29.7% YoY to Rs. 382 cr: Sharekhan
Cadila Healthcare Q3 PAT may dip 12.8% YoY to Rs. 473.7 cr: ICICI Direct
Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila
Cadila Healthcare Q2 PAT seen up 4.8% YoY to Rs. 530 cr: HDFC Securities
Cadila Q2 PAT may dip 23.3% YoY to Rs. 386 cr: Sharekhan
Cadila Healthcare Q2 PAT may dip 25.4% YoY to Rs. 375.4 cr: ICICI Direct
Pharma Q1 preview: Poised for strong performance on rebound of domestic and stable US generics biz
Global brokerages upgrade these 6 stocks to buy post Q4 results
Cadila Healthcare Q4 PAT seen up 36.5% YoY to Rs. 530 cr: HDFC Securities
Cadila Healthcare Q4 PAT seen up 39.7% YoY to Rs. 538.4 cr: Edelweiss
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key
Weak US sales, INR appreciation to drag earnings; Dr Reddy, Cadila top pick: Edelweiss
Cadila Q4 PAT seen up 19.5% to Rs 309.7 cr: ICICI Securities
View More
Home
Markets
Loans
SPIN
2
WIN
News
Portfolio